Siemens Healthineers Launches Brain Health Research Portfolio With First Biomarker Assays Now Available

Siemens Healthineers announced coming its offerings for encephalon wellness investigation are expanding, pinch nan brain-derived, afloat automated Atellica IM Phosphorylated tau 217 (pTau217) and Atellica IM Brain Derived Tau (BDTau) assays now disposable for 1. Every year, location are astir 10 cardinal caller cases of dementia diagnosed worldwide2. Alzheimer's illness is nan astir common, contributing to 60-70 % of cases, though it affects galore much group complete clip arsenic these individuals go adversely impacted and progressively limited connected others for their care2.

The humor tests from Siemens Healthineers connection researchers chemiluminescent immunoassays to supply a quantitative measurement of brain-derived phosphorylated tau 217 (p-tau217) and Brain Derived Tau (BD tau) and are tally connected nan wide installed Atellica Solution IM and Atellica CI Analyzers. Blood-based biomarker testing offers a less-invasive method compared to cerebrospinal fluid which requires a lumbar puncture.

Siemens Healthineers is laser focused connected expanding researchers' entree to humor testing that tin trim nan load of invasive testing to amended understand these diseases and thief reside nan increasing societal effect of neurodegenerative conditions. Our Atellica IM instrumentality enables nan precocious sensitivity required to observe neurological biomarkers successful blood."

Jim Freeman, Head of Core Laboratory Solutions R&D for Diagnostics, Siemens Healthineers

"Analyzer engineering is very important for amplifying nan awesome we request to execute reliable results utilizing humor tests," said Henrik Zetterberg, MD, PhD, an internationally renowned neuroscientist known for his pioneering investigation connected biomarkers of Alzheimer's illness and different neurodegenerative disorders. "Blood tests are overmuch easier for some patients and doctors - you tin standard testing, travel patients, aliases possibly hole a biomarker portfolio."

Contributions to technological innovation

Siemens Healthineers is progressive successful respective investigation collaborations to beforehand earlier discovery and characterization of neurological diseases pinch p-tau217 and BD tau biomarkers3-5. Notably, multi-cohort investigation studies are underway pinch PREDICTOM, ACCESS-AD, and Banner Sun Health Research Institute.

"We worth nan opportunity to activity pinch nan starring diagnostics companies to beforehand nan conflict against Alzheimer's disease, and this is simply a awesome example," said Nicholas Ashton, PhD, elder head of nan Fluid Biomarker Program astatine Banner Sun Health Research Institute successful Arizona. "We're moving to validate nan objective inferior of nan plasma p-tau217 biomarker crossed divers diligent populations to beforehand early discovery of Alzheimer's disease. Our findings look to support nan committedness of this Alzheimer's humor biomarker successful nan objective setting. We look guardant to further advancing this research."

Other encephalon wellness biomarkers

In summation to nan Atellica IM pTau217 and Atellica IM BDTau RUO assays, Siemens Healthineers offers a assay (with CE mark)6 to thief foretell nan consequence of early Multiple Sclerosis illness activity. Development efforts are underway to connection further biomarkers, including Apolipoprotein E-ε4 (ApoE-ε4), a macromolecule progressive successful nan metabolism of fats and a subtype that is implicated successful Alzheimer's illness and cardiovascular diseases. Researchers tin enactment updated astir these offerings